Copenhagen (awp / afp) – Driven by the sale of its treatments for obesity and diabetes, the world number one in insulin, the Danish Novo Nordisk recorded in 2021 a net profit up 13%.
Turnover increased by 14%, at constant exchange rates, to 140.8 billion crowns (18.9 billion euros) thanks to sales of anti-obesity drugs (+55%) ahead of those of drugs analogous to GLP-1, an intestinal hormone that secretes insulin, which increased by 32%, with in particular Rybelsus, an oral anti-diabetic (+158%).
afp/lk